tiprankstipranks
Advertisement
Advertisement

Optimi Health Ships MDMA to Australia for PTSD Treatment Programs

Story Highlights
  • Optimi Health exported 1,000 MDMA capsules to Australia for authorized PTSD treatment programs under the Authorised Prescriber Scheme.
  • The shipment, supporting over 300 therapy sessions, boosts Optimi’s presence in Australia’s psychedelic medicines market and underpins major real-world evidence research.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Optimi Health Ships MDMA to Australia for PTSD Treatment Programs

Claim 55% Off TipRanks

Optimi Health ( (TSE:OPTI) ) has issued an update.

Optimi Health has completed its first MDMA export of 2026 to Australia, shipping 1,000 standardized 60 mg capsules for use in authorized clinical programs treating Post-Traumatic Stress Disorder under the country’s Authorised Prescriber Scheme. The batch, sufficient for more than 300 MDMA-assisted therapy sessions, strengthens Optimi’s role in Australia’s emerging psychedelic treatment market and supports extensive real-world evidence gathering by the Australian National University, while its Australian pharmacy partner distributes the product to clinics nationwide under existing reimbursement and regulatory frameworks aimed at veterans and other PTSD patients.

The most recent analyst rating on (TSE:OPTI) stock is a Hold with a C$0.34 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.

Spark’s Take on TSE:OPTI Stock

According to Spark, TipRanks’ AI Analyst, TSE:OPTI is a Neutral.

The score is primarily held down by weak financial performance (declining small revenue, negative margins, persistent losses and cash burn, and higher leverage). Technicals provide only modest support with a neutral momentum profile and price above the 200-day average, while valuation is constrained by negative earnings (negative P/E) and no dividend yield data.

To see Spark’s full report on TSE:OPTI stock, click here.

More about Optimi Health

Optimi Health Corp. is a Health Canada-licensed, GMP-compliant pharmaceutical manufacturer focused on prescribed psychedelic treatments for mental health therapies. From two 10,000-square-foot facilities in British Columbia, the company produces validated MDMA and botanical psilocybin products, supplying active pharmaceutical ingredients and finished dosage forms to regulated channels in Australia and Canada.

Average Trading Volume: 82,794

Technical Sentiment Signal: Buy

Current Market Cap: C$32.86M

Learn more about OPTI stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1